- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05369650
To Explore the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine in Patients
May 10, 2022 updated by: Chunling Jiang, West China Hospital
A Pilot Study on the Safety and Efficacy of Intravenous Infusion of Different Doses of Lidocaine for Postoperative Analgesia in Patients With Open Hepatectomy
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1, lidocaine group 1.5, and lidocaine group 2, 1% lidocaine 1.5 mg/kg was intravenously infused with a micropump after anesthesia induction, and the infusion was completed within 10 minutes according to the ideal body weight, and then continued for 1% lidocaine was infused at 1 mg/kg.h,
1.5 mg/kg.h
and 2 mg/kg.h
respectively until the end of the operation.
In the placebo group, the same volume of normal saline was used instead.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
All patients who met the inclusion criteria were randomly divided into four groups, 30 cases in each group, which were lidocaine group 1, lidocaine group 1.5, lidocaine group 2, and the placebo group In lidocaine group 1, lidocaine group 1.5, and lidocaine group 2, 1% lidocaine 1.5 mg/kg was intravenously infused with a micropump after anesthesia induction, and the infusion was completed within 10 minutes according to the ideal body weight, and then continued for 1% lidocaine was infused at 1 mg/kg.h,
1.5 mg/kg.h
and 2 mg/kg.h
respectively until the end of the operation.
In the placebo group, the same volume of normal saline was used instead.Postoperative pain management during the first 72 postoperative hours will involve the use of a PCIA device, which will contain lidocaine 30mg/kg, sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9 % normal saline.
In the placebo group, the same volume of normal saline will be administered during anesthesia.
The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
All the background infusions of PCIA will set at 2 ml/h, the bolus volume of each PCIA press is 2 ml and the lockout interval is 15 min.
Study Type
Interventional
Enrollment (Anticipated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- West China Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age: 18-70 years old
- American Society of Anesthesiologists(ASA) Ⅰ~III
- BMI≤30
- Intended for open liver resection Exclusion criteria:1. Long-term opioid users 2. Patients with contraindications or allergies to any drugs (lidocaine, etc.) used in this study 3. Patients with severe hepatic insufficiency before surgery (defined as total bilirubin>1.46mg/dl), renal insufficiency (glomerular filtration rate <30ml/min/1.73m2 or end-stage renal disease) 4. Associated with severe heart disease (second or third degree atrioventricular block); severe heart failure (ejection fraction <50%); sinus bradycardia; patient 6. Patients who participated in other clinical trials within 3 months before enrollment in the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
EXPERIMENTAL: Lidocaine 1 group
After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1mg/kg.h
(ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h
after operation to 72h after operation.
|
The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine.
1mg/kg.h,
1.5mg/kg.h,
2mg/kg.h
(ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg
after surgery.
h to 72h after surgery.
|
|
EXPERIMENTAL: Lidocaine 1.5 group
After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 1.5mg/kg.h
(ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h
after operation to 72h after operation.
|
The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine.
1mg/kg.h,
1.5mg/kg.h,
2mg/kg.h
(ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg
after surgery.
h to 72h after surgery.
|
|
EXPERIMENTAL: Lidocaine 2 group
After induction of anesthesia, 1% lidocaine 1.5mg/kg (ideal body weight, 10min pumped) was injected intravenously with a micro pump, and then 1% lidocaine 2mg/kg.h
(ideal body weight) was continuously pumped until the end of the operation , connected to patient-controlled intravenous analgesia (PCIA) pump containing lidocaine 0.3-1.5mg/kg.h
after operation to 72h after operation.
|
The lidocaine group 1, 1.5 and 2 groups were injected with 1% lidocaine 1.5mg/kg (ideal body weight, 10min infusion) after anesthesia induction, respectively, and then continued to infuse 1% lidocaine.
1mg/kg.h,
1.5mg/kg.h,
2mg/kg.h
(ideal body weight) until the end of the operation, and a patient-controlled intravenous analgesia (PCIA) pump containing lidocaine (PCIA) 0.3-1.5mg/kg
after surgery.
h to 72h after surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Immediate postoperative plasma lidocaine concentration
Time Frame: Immediately after surgery
|
Plasma lidocaine concentration is an important indicator for evaluating the safety of the drug during use
|
Immediately after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Bowel function recovery
Time Frame: At 3 days after surgery
|
defined as the time to first defecation or time to first flatus
|
At 3 days after surgery
|
|
Plasma lidocaine concentration immediately after loading
Time Frame: 30 minutes before surgery
|
Plasma lidocaine concentration is an important indicator for evaluating the safety of the drug during use
|
30 minutes before surgery
|
|
24-hour postoperative plasma lidocaine concentration
Time Frame: 24-hour postoperative
|
Plasma lidocaine concentration is an important indicator for evaluating the safety of the drug during use
|
24-hour postoperative
|
|
The incidence of lidocaine toxicity within 72 hours after operation
Time Frame: within 72 hours after operation
|
Lidocaine toxicity mainly includes neurological manifestations such as dizziness, tinnitus, convulsions, cardiac manifestations such as bradycardia, new severe atrioventricular block and so on.
|
within 72 hours after operation
|
|
The incidence of moderate to severe pain at 24、48 and 72 hours after surgery at rest and during movement;
Time Frame: 24,48 and 72 hours after surgery
|
he pain is evaluated using numerical rating scale(NRS).
NRS scores range from 0 to 10 points, with 0 points representing no pain, 1-3 points representing mild pain, 4-6 points representing moderate pain, 7-9 points representing severe pain and 10 points representing the strongest pain.
|
24,48 and 72 hours after surgery
|
|
The cumulative morphine consumption at 24, 48 and 72 hours postoperatively
Time Frame: At the end of the surgery,24,48 and 72 hours after surgery
|
intra-operative and postoperative opioid use is reported as morphine milligram
|
At the end of the surgery,24,48 and 72 hours after surgery
|
|
Postoperative hospital stay
Time Frame: up to 30 days
|
The days of hospital stay after the operation were calculated from the first day after the operation to the days of discharge.
|
up to 30 days
|
|
Patient satisfaction scores
Time Frame: 72 hours after surgery
|
(satisfaction scores regarding pain control and the overall recovery process were obtained at 72 hours after surgery, using a 11-point Likert scale, with 0 indicating "very dissatisfied"and10 indicating "very satisfied"
|
72 hours after surgery
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 27, 2019
Primary Completion (ANTICIPATED)
May 27, 2022
Study Completion (ANTICIPATED)
September 27, 2022
Study Registration Dates
First Submitted
May 4, 2022
First Submitted That Met QC Criteria
May 10, 2022
First Posted (ACTUAL)
May 11, 2022
Study Record Updates
Last Update Posted (ACTUAL)
May 11, 2022
Last Update Submitted That Met QC Criteria
May 10, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Liver Diseases
- Liver Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Lidocaine
Other Study ID Numbers
- 2019-11 (APHM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.